Open access · CC-BY
via OpenAlex
The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials
Alzheimer s & Dementia · 2018 · ▲ 138 citations
Abstract
INTRODUCTION: The National Institute on Aging-Alzheimer's Association Research Framework on Alzheimer's disease (AD) represents an important advance in the biological characterization of the AD spectrum. METHODS: The National Institute on Aging-Alzheimer's Association Framework is considered as it applies to clinical trials. RESULTS: Using the combination of amyloid (A), tau (T), and neurodegeneration (N) biomarkers, the Framework provides a means of defining the state of patients with regard to Alzheimer pathologic change. The Framework is relevant to clinical trials of disease-modifying agents, allowing participants to be characterized biologically at baseline. The ATN Framework can also inform trial outcomes. The preclinical phase of the disease after amyloid deposition is defined by A+T-N-, and the transition to prodromal disease and dementia is characterized by the addition of T and N. Most symptomatic patients in clinical trials are in the class of A+T+N- and A+T+N+. DISCUSSION: The National Institute on Aging-Alzheimer's Association Framework on AD represents progress in providing biomarker profiles of participants in the AD spectrum that can be used to help design clinical trials.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.jalz.2018.05.006
- Canonical
- link ↗
- Fetched
- 2026-10-16 MST
Cite this
APA
Cummings, J.L. (2018). The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. <em>Alzheimer s & Dementia</em>. https://doi.org/10.1016/j.jalz.2018.05.006
Vancouver
Cummings JL. The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials. Alzheimer s & Dementia. 2018. doi:10.1016/j.jalz.2018.05.006.
BibTeX
@article{jeffrey2018TheNat,
title = {The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials},
author = {Jeffrey L. Cummings},
journal = {Alzheimer s & Dementia},
year = {2018},
doi = {10.1016/j.jalz.2018.05.006},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Alzheimer s & Dementia 2018
Preprint · OA
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Ascidian Therapeutics, Inc 2024
Open access · US-GOV
Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials
Alzheimer s & Dementia 2011
Open access · OA
The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Alzheimer s & Dementia 2018
Open access · CC-BY
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Alzheimer s & Dementia 2011
Citation only
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Innovation in aging 2025
Open access · OA